Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Immunology
Импакт фактор: 1.352 5-летний Импакт фактор: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Печать: 1040-8401
ISSN Онлайн: 2162-6472

Выпуски:
Том 39, 2019 Том 38, 2018 Том 37, 2017 Том 36, 2016 Том 35, 2015 Том 34, 2014 Том 33, 2013 Том 32, 2012 Том 31, 2011 Том 30, 2010 Том 29, 2009 Том 28, 2008 Том 27, 2007 Том 26, 2006 Том 25, 2005 Том 24, 2004 Том 23, 2003 Том 22, 2002 Том 21, 2001 Том 20, 2000 Том 19, 1999 Том 18, 1998 Том 17, 1997 Том 16, 1996 Том 15, 1995 Том 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v29.i6.10
pages 443-468

Regulation of Allergy with RNA Interference

Motohiko Suzuki
Departments of Surgery and Pathology, University of Western Ontario, London, Ontario, Canada; Department of Otorhinolaryngology, Nagoya City University, Nagoya, Japan
Xiufen Zheng
Departments of Surgery and Pathology, University of Western Ontario, London, Ontario
Xusheng Zhang
Departments of Surgery and Pathology, University of Western Ontario, London, Ontario
Yuwei Zhang
Medistem Laboratories, San Diego, CA
Thomas E. Ichim
Departments of Surgery and Pathology, University of Western Ontario, London, Ontario, Canada; Medistem Laboratories, San Diego, CA
Weiping Min
Departments of Surgery and Pathology, University of Western Ontario, London, Ontario

Краткое описание

Allergic diseases such as asthma, allergic rhinitis, allergic conjunctivitis, and atopic dermatitis are clinically challenging. Although current treatments such as antihistamines, leukotriene receptor antagonists, and corticosteroids are effective at reducing symptoms, they do not address the underlying cause of the allergic response. Therefore, novel therapies that target upstream causative events in allergic diseases are desirable. The induction of RNA interference (RNAi) by small interfering RNA (siRNA) is a potent method for specifically knocking down molecular targets. Gene modulation by siRNA is therapeutically promising, with clinical safety and feasibility already demonstrated. However, to our knowledge, the use of siRNA in the area of allergic disease has been limited. Recently, we demonstrated the inhibition of CD40 by siRNA as a means of inhibiting allergic reactions. RNAi-based therapies represent a novel and promising strategy for the control of both the symptoms of allergy and the cause of the allergic response. Here we discuss the potential of siRNA in the treatment of allergic diseases by focusing on molecular and cellular interactions involved in the allergic cascade.


Articles with similar content:

A CCL2-Based Fusokine as a Novel Biopharmaceutical for the Treatment of CCR2-Driven Autoimmune Diseases
Critical Reviews™ in Immunology, Vol.30, 2010, issue 5
Jacques Galipeau, Moutih Rafei
Modulation of Immune Responses by Histone Deacetylase Inhibitors
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 1-2
Heiko Brennenstuhl, Ulrike Naumann, Sonja Schotterl
Opposing Forces in Asthma: Regulation of Signaling Pathways by Kinases and Phosphatases
Critical Reviews™ in Immunology, Vol.29, 2009, issue 5
Philippe Pouliot, Martin Olivier
Mechanisms of Yin Yang 1 in Oncogenesis: The Importance of Indirect Effects
Critical Reviews™ in Oncogenesis, Vol.16, 2011, issue 3-4
Michael L. Atchison, Kristina Zaprazna, Arindam Basu, Madhusudhan Papasani
Deacetylation of Chromatin and Gene Expression Regulation: A New Target for Epigenetic Therapy
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 1-2
Heidi Olzscha, Nicholas B. La Thangue, Semira Sheikh